MESOBLAST'S PRECLINICAL TRIAL RESULTS OF INTRACORONARY CELL THERAPY PUBLISHED IN CIRCULATION RESEARCH
May 14 2013 - 9:04PM
Mesoblast's preclinical trial results of its allogeneic, or
"off-the-shelf", Mesenchymal Precursor Cells (MPC) delivered by
intracoronary infusion in acute myocardial infarction (AMI) have
been published in the May 2013 issue of Circulation Research, the
leading research journal of the American Heart Association. The
scientific publication, entitled "Intracoronary Infusion of
Allogeneic Mesenchymal Precursor Cells Directly Following
Experimental Acute Myocardial Infarction Reduces Infarct Size,
Abrogates Adverse Remodeling and Improves Cardiac Function", can be
viewed at
http://circres.ahajournals.org/content/early/2013/05/08/CIRCRESAHA.112.300730
The study was performed at the Thoraxcenter, Erasmus University
Medical Center, Rottterdam, and was led by Professor Eric Duckers.
In the randomized study of 68 sheep, intracoronary infusion of
allogeneic MPC directly after an anterior AMI was found to be safe,
feasible, and markedly effective. A single intracoronary MPC
infusion decreased infarct size by 40%, abrogated left ventricular
adverse remodelling, resulted in a marked reduction of left
ventricular volumes, increased small and larger blood vessel
density by 71% (capillaries) and 127% (arterioles), and prevented
heart failure. These effects of MPC treatment on infarct size and
myocardial perfusion resulted in a significant improvement of both
global and regional cardiac function. The results of this study
form the scientific basis for the current AMICI trial (Allogeneic
Mesenchymal precursor cell Infusion in myoCardial Infarction), the
first trial to evaluate an allogeneic cellular therapy for AMI
delivered by intracoronary infusion. The Phase 2A/2B trial is
recruiting in Europe, Australia, and New Zealand. Professor Duckers
is the Principal Investigator of the AMICI trial. Mesoblast Limited
Mesoblast Limited is a world leader in the development of biologic
products for the broad field of regenerative medicine. Mesoblast's
patented Mesenchymal Precursor Cell (MPC) technology is being
developed for an extensive range of major clinical diseases,
including inflammatory and immunologic conditions of the joints and
lungs, diabetes and kidney disease, orthopedic spine conditions,
and cardiovascular disorders. www.mesoblast.com
CONTACT: Julie Meldrum
Global Head of Corporate Communications
Mesoblast Limited
T: + 61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2024 to May 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From May 2023 to May 2024